Artikel ; Online: The in vitro effects of vitamin 1, 25(OH) 2 D3 on expression of cytokines: In new-onset systemic lupus erythematosus patients.
2022 Band 31, Heft 8, Seite(n) 939–943
Abstract: Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting a variety of factors in the immune system. Awareness of the role of cytokines in SLE has led to new clinical perspectives in its pathogenesis; therefore, the aim of ...
| Abstract | Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting a variety of factors in the immune system. Awareness of the role of cytokines in SLE has led to new clinical perspectives in its pathogenesis; therefore, the aim of this study was to investigate the effect of vitamin 1, 25(OH) 2 D3 (D3) on the expression of IL-2, IL-4, IL-5, IL-10, and IFN-γ cytokines in patients with lupus. Methods: A total of 65 new-onset SLE patients were enrolled in the study. After peripheral blood mononuclear cell isolation, the lymphocytes of each patient were divided into two groups, one treated with a concentration of 50 μmol vitamin D3 (test) and the other untreated with vitamin D3 (control), were cultured. After 24 hours, the cultured cells were collected and the expressions of IL-2, IL-4, IL-5, IL-10, and IFN-γ genes were analyzed by RT-qPCR. Results: It was observed that vitamin D3 reduced expression of IFN-γ, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% ( Conclusion: With different patterns of cytokine changes in patients with lupus in different studies, it seems that the pattern of cytokine changes is largely dependent on the phase of the disease and with this study it can be concluded that vitamin D3 administration at the time of diagnosis and in the early stages and before starting treatment have different effects from its administration in the acute stage of the disease, which requires further studies to prove. It seems that in patients with systemic lupus erythematosus, vitamin D should be administered taking into account the phase of the disease. |
|---|---|
| Mesh-Begriff(e) | Cholecalciferol/pharmacology ; Cytokines/genetics ; Humans ; Interleukin-10/genetics ; Interleukin-2/genetics ; Interleukin-4 ; Interleukin-5 ; Leukocytes, Mononuclear ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/genetics ; Vitamin D ; Vitamins/pharmacology ; Vitamins/therapeutic use |
| Chemische Substanzen | Cytokines ; Interleukin-2 ; Interleukin-5 ; Vitamins ; Interleukin-10 (130068-27-8) ; Vitamin D (1406-16-2) ; Cholecalciferol (1C6V77QF41) ; Interleukin-4 (207137-56-2) |
| Sprache | Englisch |
| Erscheinungsdatum | 2022-04-29 |
| Erscheinungsland | England |
| Dokumenttyp | Journal Article |
| ZDB-ID | 1154407-7 |
| ISSN | 1477-0962 ; 0961-2033 |
| ISSN (online) | 1477-0962 |
| ISSN | 0961-2033 |
| DOI | 10.1177/09612033221098533 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 3717: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.